` QNRX (Quoin Pharmaceuticals Ltd) vs S&P 500 Comparison - Alpha Spread

Q
QNRX
vs
S&P 500

Over the past 12 months, QNRX has underperformed S&P 500, delivering a return of -22% compared to the S&P 500's +14% growth.

Stocks Performance
QNRX vs S&P 500

Loading
QNRX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
QNRX vs S&P 500

Performance Gap Between QNRX and GSPC
HIDDEN
Show

Performance By Year
QNRX vs S&P 500

Loading
QNRX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Quoin Pharmaceuticals Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Quoin Pharmaceuticals Ltd
Glance View

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

QNRX Intrinsic Value
HIDDEN
Show
Back to Top